" class="no-js "lang="en-US"> VectorY and Annogen Announces Research for CNS-cell Promoters
Saturday, May 18, 2024

VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY’s vectorized antibody programs.

Using its proprietary Survey of Regulatory Elements (SuRE™) technology, Annogen functionally annotates the entire human non-coding genome to identify regulatory DNA elements that control therapeutic gene expression for gene & cell therapy. Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner. The SuRE™ technology is unique among other promoter-identification technologies in functionally testing non-coding promoter elements throughout the entire genome, including at remote sites where activity is regulated.

“We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative diseases such as ALS,” Sander van Deventer CEO of VectorY said.

VectorY is a leader in the development of transformative vectorized antibody therapies for neurodegenerative diseases with high unmet medical need. With extensive internal knowhow, a unique proprietary platform has been assembled that combines state-of-the-art therapeutic antibodies, capsids, and manufacturing to enable efficient delivery of one-time precision treatments to the CNS. VectorY is advancing a pipeline of potentially disease-modifying treatments for devastating neurodegenerative diseases, including ALS, Huntington’s, and Parkinson’s disease.

“VectorY is a leading example of novel advanced approaches to vectorized antibody therapy development,” Joris van Arensbergen CEO of Annogen adds. “Their focus on controlling various aspects of vector design, including cell-specific promoters, proves the value we can bring with our SuRE™ technology. We are very pleased to work with this forward-thinking team and further build our track record in this field.”

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more